56% also covered for weight loss Among those that cover GLP-1s, 77% follow their PBMs authorization criteria when the medications are prescribed to manage diabetes
Figure 1 shows a schematic representation of the origin of GLP-1 via proglucagon
In DCF oxidation (Fig
Consistent findings across other paediatric trials Multiple RCTs including Zimmerman et al., 2021, Momtazmanesh et al., 2020, and Ou et al., 2024 also showed improvements in repetitive behaviours, hyperactivity, irritability, and overall ASD symptom severity, matching the percentage trends above
The general trend is improvement over the first weeks of GLP-1 treatment as the body adapts
Myth: You can take extra doses to speed up results Dangerous and false